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2. The ALBATROSS (Aldosterone Lethal Effects Block-
ade in Acute Myocardial Infarction Treated With or 
Without Reperfusion to Improve Outcome and Survival 
at Six Months Follow-up) trial failed to show that al-
dosterone antagonists were beneficial to patients with 
myocardial infarction without heart failure.
3. The PRomPT (Post-Myocardial Infarction Remodelling 
Prevention Therapy) trial showed that peri-infarct pac-
ing did not prevent left ventricular remodelling or im-
prove functional, or clinical outcomes during 18 months 
of follow-up in patients with a large first myocardial 
infarction.
4. The OPTIDUAL (Optimal Duration of Dual Antiplate-
let Therapy After Drug-eluting Stent Implantation) trial 
aimed to evaluate dual antiplatelet therapy (DAPT) for 
an additional 36 months among subjects who received 
a drug-eluting stent and were event-free at 12 months. 
The trial failed to reach primary outcome; however, 
extended duration of DAPT non-significantly reduced 
ischaemic events without increasing bleeding.
5. The ARTS-HF (Mineralocorticoid Receptor AnTagonist 
Study In Heart Failure) trial failed to show a reduction 
in NT-proBNP levels for finerenone versus eplerenone; 
however, secondary outcomes favoured finerenone.
6. The TECOS (Trial Evaluating Cardiovascular Out-
comes with Sitagliptin) trial showed that sitagliptin 
improves glycaemic control without increasing adverse 
cardiovascular events. Among diabetic subjects with 
documented cardiovascular disease, sitagliptin was non-
inferior to placebo on the outcome of adverse cardiovas-
cular events.
7. The ELIXA (Evaluation of Lixisenatide in Acute Coro-
nary Syndrome) study evaluated treatment with lix-
isenatide versus placebo in patients with type 2 diabetes 
presenting with an acute coronary syndrome. Although 
At the ESC Congress 2015 in London, six different Hot Line 
sessions were organised. The six topics were acute myo-
cardial infarction, atrial fibrillation/pacing, diabetes/phar-
macology, hypertension, heart failure, and coronary artery 
disease. Hot Line sessions are usually the main attraction of 
the ESC Congress as novel data are being presented for the 
first time [1]. Altogether 26 novel studies were presented 
during the six Hot Line sessions. All these Hot Line studies 
will be reported in detail in a special NHJ supplement that 
is added to this November edition of our journal. Therefore, 
the outcomes of all these trials will not be addressed here.
The focus of this Comment is to briefly highlight those 
trials that had a negative (or neutral) outcome. Over the past 
years, trials with a negative outcome seem to outnumber tri-
als with a positive outcome during the annual ESC Con-
gresses [2, 3]. The following studies mentioned below had 
a negative outcome for their primary endpoints at the ESC 
Congress 2015 in London.
1. The CIRCUS (Does Cyclosporine Improve Clinical 
Outcome in ST-elevation Myocardial Infarction Pa-
tients?) trial failed to show that cyclosporine improved 
clinical outcomes or prevented adverse left ventricular 
remodelling in anterior ST-segment elevation myocardi-
al infarction (STEMI). The goal of the trial was to evalu-
ate treatment with cyclosporine compared with placebo 
among subjects undergoing primary percutaneous coro-
nary intervention for anterior STEMI.
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lixisenatide showed significant changes in biomarkers, 
a neutral effect upon cardiovascular death, myocardial 
infarction and stroke was found.
8. The SCOT (Standard Care versus Celecoxib Outcome 
Trial) showed that adverse cardiovascular event rates 
were similar between celecoxib and nonselective non-
steroidal anti-inflammatory drugs (NSAID). The goal of 
the trial was to evaluate treatment with celecoxib com-
pared with a nonselective NSAID among subjects with 
arthritis and no known cardiovascular disease.
9. The MATRIX (Minimizing Adverse Hemorrhagic 
Events by Transradial Access Site and Systemic Imple-
mentation of AngioX) trial showed that bivalirudin did 
not reduce major or net adverse events versus heparin; 
however, bleeding/death was reduced and stent throm-
bosis increased. Several lines of evidence even suggest 
an increased risk of stent thrombosis with bivalirudin.
10. The BENEFIT (BENznidazole Evaluation For Inter-
rupting Trypanosomiasis) study showed that benzni-
dazole did not reduce progression of Chagas disease 
cardiomyopathy among patients with Chagas disease. 
However, it was found that a 40–80 day treatment with 
this antiparasitic medication significantly reduced para-
sitic activity in the blood.
11. The UNDER-ATP (Atrial Fibrillation/Pacing Adenosine 
Triphosphate) trial showed that guided pulmonary vein 
isolation in comparison to conventional pulmonary vein 
isolation did not reduce late recurrence atrial fibrillation 
at 1 year follow-up.
12. The PRESERVATION I showed that a novel Bioabsorb-
able Cardiac Matrix (BCM) is safe but does not benefit 
STEMI patients with large infarcts; it does not prevent 
left ventricular remodelling or other adverse outcomes.
13. The ‘Optimization of Heart Failure Management Using 
Medtronic OptiVol Fluid Status Monitoring and Care-
Link Network’ (OptiLink) study assessed the effect of 
intrathoracic impedance monitoring, through automatic 
wireless telemedicine notification on all-cause death and 
cardiovascular hospitalization. The primary composite 
endpoint did not differ between the two groups (tele-
medicine guided system or controls).
14. The ‘Calcium Up-Regulation by Percutaneous Admin-
istration of Gene Therapy in Cardiac Disease Phase 2b’ 
(CUPID2) trial, investigating the efficacy and safety of 
intracoronary administration of adeno-associated virus 
type I (AAV1)/SERCA2a in patients with advanced 
heart failure, showed that treatment with AAV1/SER-
CA2a was safe but failed to improve the rate of recur-
rent events as well as the time to the first terminal event.
15. The ‘Treatment of Sleep-Disordered Breathing with 
Predominant Central Apnoea with Adaptive Servo-Ven-
tilation in Patients with Chronic Heart Failure’ (SERVE-
HF) showed that the composite primary endpoint (time 
to first event of all-cause death, life-saving intervention, 
or unplanned hospitalization for chronic heart failure) 
did not differ between intervention and control group. 
In fact, all-cause death and cardiovascular death were 
elevated in the treatment arm.
At a first glance the ‘negative’ outcomes of these trials 
seem rather disappointing. One could therefore really won-
der whether all Hot Line studies were truly hot. However, 
it should be realised that the label ‘positive’ or ‘negative’ 
hinges on a p-value of < 0.05 or > 0.05; this might in prin-
ciple have nothing to do with the clinical implication of a 
study, be it positive or negative. Secondly, ‘negative’ usu-
ally only applies to the primary endpoint; in some instances 
the drugs studied in the above-mentioned trials showed 
improved safety beyond the neutral finding. Finally, the ulti-
mate proof of the value of a large clinical study is incorpora-
tion into the guidelines [4–8].
Nevertheless, there is a flipside of the coin. Sometimes one 
cannot escape the feeling that also in science there is a l’art 
pour l’art approach; are all the above-described studies really 
needed? Are the studies truly hypothesis-driven? Will the out-
come of the study change the treatment policy for the individ-
ual patient? Finally, will it impact the existing guidelines [9, 
10]? Therefore, the impression occasionally arises that some 
studies are primarily performed for the sake of the industry, 
followed by the urge of the researchers, and lastly in the inter-
est of the patient. I sincerely hope this impression is false.
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